Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levomethorphan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2A known ✓ | Q12879 | 7/20 | 0.95 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 6/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.98 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.95 |
| ▸ | GRIN2D | O15399 | 6/20 | 0.95 |
| ▸ | GRIN3B | O60391 | 6/20 | 0.95 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.95 |
| ▸ | GRIN2C | Q14957 | 6/20 | 0.95 |
| ▸ | GRIN3A | Q8TCU5 | 6/20 | 0.95 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.95 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.95 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.95 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.95 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.95 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.95 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.95 |
| ▸ | TSHR | P16473 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dextromethorphan SCHEMBL29359586 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Racemethorphan SCHEMBL4894005 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL121923 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL1321395 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL4532860 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Racemethorphan SCHEMBL30052214 | 1.00 | CYP2D6 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL4882307 | 0.99 | CYP2D6 (0.98) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL121924 | 0.99 | CYP3A4 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Dextromethorphan SCHEMBL3325972 | 0.99 | GRIN1 (0.98) | CYP2D6LMNAPMP22CYP3A4GRIN1 | |
| Racemethorphan SCHEMBL6855351 | 0.99 | CYP3A4 (1.00) | CYP2D6LMNAPMP22CYP3A4GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150056288-A1 | MODIFIED RELEASE LIQUID PHARMACEUTICAL COMPOSITION COMPRISING BROMOPHENIRAMINE, PSEUDOEPHEDRINE AND DEXTROMETHORPHAN | WOCKHARDT LIMITED (IN) | 2015-02-26 | — | — | US | disclosed |
| US-20080090878-A1 | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders | BILLSTEIN STEPHAN A | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150056288-A1 | MODIFIED RELEASE LIQUID PHARMACEUTICAL COMPOSITION COMPRISING BROMOPHENIRAMINE, PSEUDOEPHEDRINE AND DEXTROMETHORPHAN | QDPR, CYP3A43, CYP2D6 | GRIN2A 915/4885SIGMAR1 12/4885CYP2D6 3/4885 |
| US-20080090878-A1 | Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders | MLNR, HTR4, HTR3D | GRIN2A 2226/4885SIGMAR1 289/4885CYP2D6 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.